Acurx Pharmaceuticals, Inc.
ACXPNasdaqCIK 1736243HealthcareFiscal year ends Dec 31
Reports and events: 82 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2917:20 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001104659-26-120279 |
| 2026-10-1616:30 ET | 8-K | 5.07 Shareholder vote results | 0001104659-26-116632 |
| 2026-09-0816:27 ET | S-1 | Registration statement | 0001104659-26-105917 |
| 2026-09-0116:15 ET | DEF 14A | Proxy statementPeriod 2026-10-16 | 0001104659-26-104316 |
| 2026-08-1316:07 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001104659-26-095904 |
| 2026-05-1116:05 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001104659-26-058631 |
| 2026-05-0416:09 ET | S-1 | Registration statement | 0001104659-26-054887 |
| 2026-05-0416:08 ET | S-1 | Registration statement | 0001104659-26-054884 |
| 2026-04-1608:14 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-044093 |
| 2026-03-1216:06 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001104659-26-027052 |
| 2026-03-0908:59 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-025003 |
| 2026-02-0216:48 ET | S-1 | Registration statement | 0001104659-26-009266 |
| 2025-11-1207:00 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001104659-25-109698 |
| 2025-10-2016:01 ET | S-1 | Registration statement | 0001104659-25-100800 |
| 2025-09-2216:42 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001104659-25-092166 |
| 2025-09-1917:16 ET | 8-K | 5.07 Shareholder vote results | 0001104659-25-091733 |
| 2025-08-1116:05 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001558370-25-011045 |
| 2025-08-0409:19 ET | DEF 14A | Proxy statementPeriod 2025-09-16 | 0001104659-25-073623 |
| 2025-07-3109:29 ET | 8-K | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-072529 |
| 2025-07-1716:06 ET | 8-K | 5.07 Shareholder vote results | 0001104659-25-068659 |
| 2025-07-1520:22 ET | S-1 | Registration statement | 0001104659-25-067841 |
| 2025-06-2008:00 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-060902 |
| 2025-05-2916:05 ET | DEF 14A | Proxy statementPeriod 2025-07-17 | 0001104659-25-054235 |
| 2025-05-2116:16 ET | S-1 | Registration statement | 0001104659-25-051615 |
| 2025-05-1307:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-047566 |
| 2025-05-1216:05 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001558370-25-007371 |
| 2025-05-0816:30 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001104659-25-046167 |
| 2025-04-0416:02 ET | S-1 | Registration statement | 0001104659-25-032184 |
| 2025-03-2816:10 ET | 8-K | 3.01 Delisting notice | 0001104659-25-029370 |
| 2025-03-1807:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-25-024731 |
| 2025-03-1716:05 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001558370-25-003117 |
| 2025-03-1007:35 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-021978 |
| 2025-02-2616:10 ET | 8-K | 3.01 Delisting notice | 0001104659-25-017437 |
| 2025-01-3116:11 ET | S-1 | Registration statement | 0001410578-25-000067 |
| 2025-01-0710:00 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-001586 |
| 2024-11-1307:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-117214 |
| 2024-11-1216:05 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001558370-24-015310 |
| 2024-08-0907:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-087545 |
| 2024-08-0816:05 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001558370-24-011587 |
| 2024-06-1716:14 ET | 8-K | 5.07 Shareholder vote results | 0001104659-24-072270 |
| 2024-05-1507:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-061579 |
| 2024-05-1416:05 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001558370-24-008130 |
| 2024-04-2916:07 ET | DEF 14A | Proxy statementPeriod 2024-06-17 | 0001104659-24-054014 |
| 2024-03-2916:58 ET | S-1/A | Registration statement, amended | 0001104659-24-041187 |
| 2024-03-1816:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-24-035556 |
| 2024-03-1816:06 ET | S-1 | Registration statement | 0001104659-24-035527 |
| 2024-03-1516:05 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001558370-24-003401 |
| 2023-11-1517:02 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-23-118749 |
| 2023-11-1416:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-23-118064 |
| 2023-11-1316:05 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001558370-23-018824 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 29, 2026, 17:22 ET. Listed shows no prices and gives no investment advice.